This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pazirandeh, S. Articles by Bistrian, B. R. Search for Related Content PubMed PubMed Citation Articles by Pazirandeh, S. Articles by Bistrian, B. R. Social Bookmarking                         What's this?

Supplementation of Arachidonic Acid Plus Docosahexaenoic Acid in Cirrhotic Patients Awaiting Liver Transplantation: A Preliminary Study

Sassan Pazirandeh, MD^,, Pei-Ra Ling, MD^*, Mario Ollero, PhD^*,, Fredric Gordon, MD, David L. Burns, MD and Bruce R. Bistrian, MD, PhD^*

From the ^* Nutrition/Infection Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and Lahey Clinic, Burlington, Massachusetts

Correspondence: Bruce R. Bistrian, MD, PhD, Room 605, Baker Building, One Deaconess Road, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215. Electronic mail may be sent to bbistria{at}bidmc.harvard.edu.

Background: In patients with cirrhotic liver diseases, supplementation of linoleic acid and -linolenic acid often does not alter the levels of arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), suggesting the necessity to directly provide these nutrients. Methods: In a double-blind, placebo-controlled fashion, 9 cirrhotic patients listed for liver transplantation at Lahey Clinic Center were given daily supplementation with either 10 gel caps containing 500 mg of AA and 1000 mg of DHA (AA/DHA) or 250 mg of linolenic acid (LA) and 125 mg of oleic acid (OA; OA/LA) for 6 weeks. -Tocopherol at 200 IU was provided daily. No other dietary prescription was made. Plasma fatty acid profiles were determined in triglyceride and phospholipids fractions. Plasma levels of C-reactive protein (CRP), tumor necrosis factor (TNF), interleukin 6 (IL-6), and soluble TNF receptor II (sTNFRII) were also measured. Results: Four patients receiving OA/LA and 5 patients receiving AA/DHA completed the study without evidence of any adverse effects or intolerance. The supplementation of LA, AA, and DHA effectively raised their levels in either one or both plasma lipid fractions in this limited number of subjects. DHA plus AA also lowered 22:4-6, 22:5-6, and 22:5-3, suggesting that DHA reduced the elongation and desaturation of AA and EPA. Conclusions: It is feasible to improve the liver disease–associated deficiency of AA or DHA with modest intakes of AA and DHA. Whether this maneuver will affect the systemic inflammatory responsiveness and ultimately clinical outcome will require a large-scale and well-controlled intervention.

Journal of Parenteral and Enteral Nutrition, Vol. 31, No. 6, 511-516 (2007)
DOI: 10.1177/0148607107031006511


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?